Wells Fargo & Company Akebia Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 96,099 shares of AKBA stock, worth $177,783. This represents 0.0% of its overall portfolio holdings.
Number of Shares
96,099
Previous 8,042
1094.96%
Holding current value
$177,783
Previous $14,000
600.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AKBA
# of Institutions
113Shares Held
55MCall Options Held
554KPut Options Held
246K-
Black Rock Inc. New York, NY11.6MShares$21.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.28MShares$17.2 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.6 Million11.5% of portfolio
-
Geode Capital Management, LLC Boston, MA4.54MShares$8.39 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.06MShares$7.52 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $340M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...